WALTHAM, Mass.--(BUSINESS WIRE)--N-of-One, Inc., a leading provider of molecular interpretation and therapeutic strategies for personalized cancer care, today announced a partnership with Fox Chase Cancer Center in Philadelphia, to provide molecular interpretation and treatment strategy analysis for genome sequencing and testing provided to advanced stage cancer patients through the Cancer Genome Institute at Fox Chase. Financial terms of the agreement are not disclosed.
“Leveraging our thousands of personalized interpretation and treatment strategy reports delivered to date, N-of-One is very excited to develop each Treatment Strategy Roadmap™ for Fox Chase patients”
Under the terms of the agreement, N-of-One will analyze the molecular profile and mutations identified through genome sequencing of each patient’s cancer and deliver comprehensive treatment strategy profiles, including data on approved and investigational therapies to Fox Chase physicians who have ordered the CancerCode-45 sequencing for a patient. The treatment strategy profile interprets and informs the findings from the test.
“We selected N-of-One because their team of experts coupled with their informatics framework will enable us to rapidly grow our cancer patient base and expand our program,” says Jeff Boyd, PhD, Executive Director of the Cancer Genome Institute at Fox Chase. “We are proud to be at the leading edge of this movement and excited to be partnering with N-of-One to provide the latest and most comprehensive clinical knowledge available to our patients.”
“Leveraging our thousands of personalized interpretation and treatment strategy reports delivered to date, N-of-One is very excited to develop each Treatment Strategy Roadmap™ for Fox Chase patients,” said Christine Cournoyer, Chief Executive Officer of N-of-One. “On a broader scale, we are helping hospitals design and implement comprehensive molecular diagnostics and treatment programs.”
Because N-of-One can incorporate data from any sequencing platform, diagnostic or bioinformatics system, it will integrate seamlessly with Fox Chase’s CancerCode-45 testing—which employs the most advanced DNA sequencing technology currently available, including the Ion Torrent Personal Genome Machine.
“We are pleased to be providing actionable intelligence to a talented team of physicians, bioinformatics professionals and scientists at Fox Chase, which is anticipating the future of cancer care and building strong internal capabilities to provide cutting-edge diagnostic and treatment options to its patients,” said Jennifer Levin Carter, founder and Chief Medical Officer of N-of-One. “We believe that providing access to the latest data-driven knowledge and resources from the cancer field enables oncologists and cancer centers to be leaders in a competitive health care environment, assuring their patients that they are getting the best care possible.”
About Fox Chase Cancer Center
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase’s Web site at www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427).
N-of-One, a leader in precision medicine, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinically actionable insights and therapeutic options focused on the point of care. Using the company’s PrecisionWorks™ knowledge integration platform and framework, N-of-One’s team of experts has delivered thousands of personalized, interpretative reports to oncologists and patients worldwide either directly, through agreements with provider networks (such as Fox Chase Cancer Center in Philadelphia) or through partnerships to provide interpretation services for leading diagnostic companies (such as Foundation Medicine and Clarient).
N-of-One solutions and services can incorporate data from any sequencing platform, diagnostic or bioinformatics system. PrecisionWorks also powers solutions that address the unique logistical and procedural challenges of delivering personalized cancer care by streamlining coordination among health care providers, diagnostic companies, drug and technology innovators and payers. N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.